Eleonor Borja 11/8/26 Eleonor Borja 11/8/26 New Phase 3 Psilocybin Data Suggest Repeat Dosing May Extend Benefits in Treatment-Resistant Depression Read More Eleonor Borja 11/1/26 Eleonor Borja 11/1/26 Oregon’s Regulated Psilocybin Program Shows Promise and Reveals Where Safety Systems Need to Improve Read More Eleonor Borja 10/25/26 Eleonor Borja 10/25/26 FDA Is Building a Faster Path for Psychedelic Medicines. A More Complete Care Model Is Taking Shape. Read More Eleonor Borja 10/18/26 Eleonor Borja 10/18/26 What Changes in the Brain After a First Psilocybin Experience? Read More Eleonor Borja 10/11/26 Eleonor Borja 10/11/26 Microdosing Benefits May Be Limited to Dosing Days. What the Largest Daily-Diary Study Found. Read More Eleonor Borja 10/6/26 Eleonor Borja 10/6/26 Psilocybin Protected Nerves From Chemotherapy in Mice. Human Evidence Comes Next. Read More Eleonor Borja 10/3/26 Eleonor Borja 10/3/26 Who Is Ready to Deliver Psychedelic Care? Lisa Ginzburg of Changa Institute Brings Training and Credentialing to the FDA Read More Eleonor Borja 9/27/26 Eleonor Borja 9/27/26 The VA’s New Psilocybin Trial Moves Veteran Care Into a More Consequential Phase of Research Read More Eleonor Borja 9/20/26 Eleonor Borja 9/20/26 Psilocybin Produced Higher Smoking Quit Rates Than Nicotine Patches in a Pilot Trial Read More Eleonor Borja 9/13/26 Eleonor Borja 9/13/26 Psilocybin Therapy Shows Promise for Anorexia Nervosa in Early Clinical Study Read More Eleonor Borja 9/6/26 Eleonor Borja 9/6/26 Psychedelic Medicine Is Moving Toward Clinical Practice. State Systems Can Help Lead the Way. Read More Eleonor Borja 8/30/26 Eleonor Borja 8/30/26 What Predicts a Better Outcome in Psychedelic-Assisted Therapy? Read More Eleonor Borja 8/23/26 Eleonor Borja 8/23/26 Changa Institute Adds New Mexico Psilocybin Certification Training for Licensed Professionals Read More Eleonor Borja 8/16/26 Eleonor Borja 8/16/26 Psilocybin and Longevity: Promising Data, Early Interpretations Read More Eleonor Borja 8/10/26 Eleonor Borja 8/10/26 Psilocybin and Neuroplasticity: New Human Data Suggests Setting May Matter More Than We Thought Read More Eleonor Borja 7/31/26 Eleonor Borja 7/31/26 Oregon Psilocybin Services Data: What Clinicians Need to Know Read More Eleonor Borja 7/22/26 Eleonor Borja 7/22/26 What Eli Lilly’s $3.8 Billion AtaiBeckley Deal Means for Psychedelic Medicine Read More Eleonor Borja 7/13/26 Eleonor Borja 7/13/26 Add Your Voice to the FDA’s September 2026 Public Hearing on Psychedelics Read More Eleonor Borja 7/7/26 Eleonor Borja 7/7/26 Psilocybin, Alzheimer’s Disease, and Psychedelic Practice: Why One 2026 Case Report Requires Caution Read More Lisa Ginzburg 6/23/26 Lisa Ginzburg 6/23/26 The Science and History of Psychedelics: How They Work and Where the Research Stands in 2026 Read More Older Posts
Eleonor Borja 11/8/26 Eleonor Borja 11/8/26 New Phase 3 Psilocybin Data Suggest Repeat Dosing May Extend Benefits in Treatment-Resistant Depression Read More
Eleonor Borja 11/1/26 Eleonor Borja 11/1/26 Oregon’s Regulated Psilocybin Program Shows Promise and Reveals Where Safety Systems Need to Improve Read More
Eleonor Borja 10/25/26 Eleonor Borja 10/25/26 FDA Is Building a Faster Path for Psychedelic Medicines. A More Complete Care Model Is Taking Shape. Read More
Eleonor Borja 10/18/26 Eleonor Borja 10/18/26 What Changes in the Brain After a First Psilocybin Experience? Read More
Eleonor Borja 10/11/26 Eleonor Borja 10/11/26 Microdosing Benefits May Be Limited to Dosing Days. What the Largest Daily-Diary Study Found. Read More
Eleonor Borja 10/6/26 Eleonor Borja 10/6/26 Psilocybin Protected Nerves From Chemotherapy in Mice. Human Evidence Comes Next. Read More
Eleonor Borja 10/3/26 Eleonor Borja 10/3/26 Who Is Ready to Deliver Psychedelic Care? Lisa Ginzburg of Changa Institute Brings Training and Credentialing to the FDA Read More
Eleonor Borja 9/27/26 Eleonor Borja 9/27/26 The VA’s New Psilocybin Trial Moves Veteran Care Into a More Consequential Phase of Research Read More
Eleonor Borja 9/20/26 Eleonor Borja 9/20/26 Psilocybin Produced Higher Smoking Quit Rates Than Nicotine Patches in a Pilot Trial Read More
Eleonor Borja 9/13/26 Eleonor Borja 9/13/26 Psilocybin Therapy Shows Promise for Anorexia Nervosa in Early Clinical Study Read More
Eleonor Borja 9/6/26 Eleonor Borja 9/6/26 Psychedelic Medicine Is Moving Toward Clinical Practice. State Systems Can Help Lead the Way. Read More
Eleonor Borja 8/30/26 Eleonor Borja 8/30/26 What Predicts a Better Outcome in Psychedelic-Assisted Therapy? Read More
Eleonor Borja 8/23/26 Eleonor Borja 8/23/26 Changa Institute Adds New Mexico Psilocybin Certification Training for Licensed Professionals Read More
Eleonor Borja 8/16/26 Eleonor Borja 8/16/26 Psilocybin and Longevity: Promising Data, Early Interpretations Read More
Eleonor Borja 8/10/26 Eleonor Borja 8/10/26 Psilocybin and Neuroplasticity: New Human Data Suggests Setting May Matter More Than We Thought Read More
Eleonor Borja 7/31/26 Eleonor Borja 7/31/26 Oregon Psilocybin Services Data: What Clinicians Need to Know Read More
Eleonor Borja 7/22/26 Eleonor Borja 7/22/26 What Eli Lilly’s $3.8 Billion AtaiBeckley Deal Means for Psychedelic Medicine Read More
Eleonor Borja 7/13/26 Eleonor Borja 7/13/26 Add Your Voice to the FDA’s September 2026 Public Hearing on Psychedelics Read More
Eleonor Borja 7/7/26 Eleonor Borja 7/7/26 Psilocybin, Alzheimer’s Disease, and Psychedelic Practice: Why One 2026 Case Report Requires Caution Read More
Lisa Ginzburg 6/23/26 Lisa Ginzburg 6/23/26 The Science and History of Psychedelics: How They Work and Where the Research Stands in 2026 Read More
